Skip to main content

Oncaspar Side Effects

Generic name: pegaspargase

Medically reviewed by Last updated on Mar 16, 2023.

Note: This document contains side effect information about pegaspargase. Some dosage forms listed on this page may not apply to the brand name Oncaspar.

Applies to pegaspargase: parenteral injection.

Side effects include:

Grade 3 or 4 reactions: Hypoalbuminemia, elevated serum aminotransferase concentrations, febrile neutropenia, hypertriglyceridemia, hyperglycemia, hyperbilirubinemia, pancreatitis, clotting study abnormalities, embolic and thrombotic events, hypersensitivity reactions.

No apparent difference in adverse effects following IV versus IM administration.

For Healthcare Professionals

Applies to pegaspargase: injectable solution.


The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).[Ref]


Very common (10% or more): Hypersensitivity, urticaria, anaphylactic reaction[Ref]

Nervous system

Common (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope

Rare (less than 0.1%): Posterior reversible leukoencephalopathy syndrome

Frequency not reported: Somnolence, tremor[Ref]


Common (1% to 10%): Thrombosis, embolism[Ref]


Very common (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea

Common (1% to 10%): Vomiting, stomatitis, ascites

Rare (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic

Frequency not reported: Pancreatic pseudocyst, parotitis[Ref]


Very common (10% or more): Febrile neutropenia

Common (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia

Frequency not reported: Bone marrow failure[Ref]


Very common (10% or more): Elevated transaminases

Common (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver

Rare (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure[Ref]


Common (1% to 10%): Hyperglycemia, weight decreased, decreased appetite

Frequency not reported: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia[Ref]


Common (1% to 10%): Infections, sepsis[Ref]


Common (1% to 10%): Pain in extremities[Ref]


Frequency not reported: Confusion[Ref]


Common (1% to 10%): Hypoxia[Ref]


Frequency not reported: Pyrexia[Ref]


Frequency not reported: Acute renal failure[Ref]


Very common (10% or more): Rash

Frequency not reported: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis[Ref]

Frequently asked questions


1. Product Information. Oncaspar (pegaspargase). Rhone Poulenc Rorer. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.